Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Gpr176 (G protein-coupled receptor 176) Rattus norvegicus
Analyze
Symbol:
Gpr176
Name:
G protein-coupled receptor 176
RGD ID:
621718
Description:
Predicted to have G protein-coupled receptor activity. Predicted to be involved in adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway and circadian behavior. Predicted to localize to plasma membrane. Orthologous to human GPR176 (G protein-coupled receptor 176); INTERACTS WITH 1-naphthyl isothiocyanate; ammonium chloride; amphetamine.
Type:
protein-coding
RefSeq Status:
VALIDATED
Also known as:
G-protein coupled receptor AGR9; gene model 1012, (NCBI); Gm1012; Gpr; probable G-protein coupled receptor 176; putative G protein coupled receptor; RBU-15
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
GPR176 (G protein-coupled receptor 176) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Gpr176 (G protein-coupled receptor 176) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, PhylomeDB, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Gpr176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
GPR176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
GPR176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Gpr176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
GPR176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
GPR176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Gpr176 (G protein-coupled receptor 176) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Homo sapiens (human):
GPR176 (G protein-coupled receptor 176)
Alliance
DIOPT (Ensembl Compara|HGNC|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Mus musculus (house mouse):
Gpr176 (G protein-coupled receptor 176)
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Danio rerio (zebrafish):
gpr176 (G protein-coupled receptor 176)
Alliance
DIOPT (PhylomeDB|TreeFam)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl mRatBN7.2 3 105,236,794 - 105,337,664 (-) NCBI Rnor_6.0 Ensembl 3 110,042,853 - 110,140,756 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_6.0 3 110,042,853 - 110,140,756 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_5.0 3 116,588,548 - 116,686,465 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 3 104,699,853 - 104,801,217 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 3 104,596,280 - 104,603,263 (-) NCBI Celera 3 104,154,931 - 104,254,445 (-) NCBI Celera Cytogenetic Map 3 q35 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
(+)-catechin multiple interactions ISO RGD:737562 6480464 [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of GPR176 mRNA CTD PMID:24763279 1,2-dichloroethane decreases expression ISO RGD:1619683 6480464 ethylene dichloride results in decreased expression of GPR176 mRNA CTD PMID:28960355 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of GPR176 mRNA CTD PMID:30723492 17beta-estradiol multiple interactions ISO RGD:737562 6480464 [Estradiol co-treated with TGFB1 protein] results in increased expression of GPR176 mRNA, ESR1 protein affects the reaction [Estradiol results in increased expression of GPR176 mRNA] CTD PMID:14699072 , PMID:30165855 17beta-estradiol affects expression ISO RGD:737562 6480464 Estradiol affects the expression of GPR176 mRNA CTD PMID:14699072 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1619683 6480464 Tetrachlorodibenzodioxin affects the expression of GPR176 mRNA CTD PMID:21570461 aflatoxin B1 decreases methylation ISO RGD:737562 6480464 Aflatoxin B1 results in decreased methylation of GPR176 gene CTD PMID:27153756 aflatoxin B2 increases methylation ISO RGD:737562 6480464 aflatoxin B2 results in increased methylation of GPR176 intron CTD PMID:30157460 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of GPR176 mRNA CTD PMID:16483693 amphetamine decreases expression EXP 6480464 Amphetamine results in decreased expression of GPR176 mRNA CTD PMID:30779732 benzo[a]pyrene increases expression ISO RGD:737562 6480464 Benzoapyrene results in increased expression of GPR176 mRNA CTD PMID:17879257 benzo[a]pyrene decreases methylation ISO RGD:737562 6480464 Benzoapyrene results in decreased methylation of GPR176 exon CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:737562 6480464 Benzoapyrene results in increased methylation of GPR176 3' UTR, Benzoapyrene results in increased methylation of GPR176 5' UTR CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:1619683 6480464 Benzoapyrene results in increased expression of GPR176 mRNA CTD PMID:22228805 bisphenol A decreases expression ISO RGD:737562 6480464 bisphenol A results in decreased expression of GPR176 mRNA CTD PMID:31715268 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of GPR176 mRNA CTD PMID:30816183 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of GPR176 mRNA CTD PMID:25181051 capsaicin decreases expression EXP 6480464 Capsaicin results in decreased expression of GPR176 mRNA CTD PMID:16278290 carbon nanotube increases expression ISO RGD:1619683 6480464 Nanotubes more ... CTD PMID:25554681 choline multiple interactions ISO RGD:1619683 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPR176 mRNA CTD PMID:20938992 cisplatin decreases expression EXP 6480464 Cisplatin results in decreased expression of GPR176 mRNA CTD PMID:22023808 cisplatin multiple interactions ISO RGD:737562 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of GPR176 mRNA CTD PMID:27392435 dexamethasone increases expression ISO RGD:1619683 6480464 Dexamethasone results in increased expression of GPR176 mRNA CTD PMID:22733784 dextran sulfate multiple interactions ISO RGD:1619683 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA CTD PMID:29950665 dioxygen multiple interactions ISO RGD:1619683 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of GPR176 mRNA CTD PMID:30529165 dorsomorphin multiple interactions ISO RGD:737562 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPR176 mRNA CTD PMID:27188386 doxorubicin affects response to substance ISO RGD:737562 6480464 GPR176 protein affects the susceptibility to Doxorubicin CTD PMID:16217747 entinostat increases expression ISO RGD:737562 6480464 entinostat results in increased expression of GPR176 mRNA CTD PMID:27188386 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of GPR176 mRNA CTD PMID:30307764 ferroheme b increases expression ISO RGD:1619683 6480464 Heme metabolite results in increased expression of GPR176 mRNA CTD PMID:19191707 folic acid multiple interactions ISO RGD:1619683 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPR176 mRNA CTD PMID:20938992 furan decreases methylation EXP 6480464 furan results in decreased methylation of GPR176 gene CTD PMID:27387713 furan increases expression EXP 6480464 furan results in increased expression of GPR176 mRNA CTD PMID:27387713 genistein increases expression ISO RGD:1619683 6480464 Genistein results in increased expression of GPR176 mRNA CTD PMID:32186404 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of GPR176 mRNA CTD PMID:22061828 heme b increases expression ISO RGD:1619683 6480464 Heme metabolite results in increased expression of GPR176 mRNA CTD PMID:19191707 L-methionine multiple interactions ISO RGD:1619683 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPR176 mRNA CTD PMID:20938992 methylmercury chloride decreases expression ISO RGD:737562 6480464 methylmercuric chloride results in decreased expression of GPR176 mRNA CTD PMID:28001369 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of GPR176 mRNA CTD PMID:28801915 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GPR176 mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of GPR176 mRNA CTD PMID:25729387 phenylmercury acetate decreases expression ISO RGD:737562 6480464 Phenylmercuric Acetate results in decreased expression of GPR176 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:737562 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPR176 mRNA CTD PMID:27188386 potassium chromate decreases expression ISO RGD:737562 6480464 potassium chromateVI results in decreased expression of GPR176 mRNA CTD PMID:22714537 SB 431542 multiple interactions ISO RGD:737562 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPR176 mRNA CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1619683 6480464 Silicon Dioxide results in increased expression of GPR176 mRNA CTD PMID:29203145 , PMID:29341224 tetrachloromethane affects expression ISO RGD:1619683 6480464 Carbon Tetrachloride affects the expression of GPR176 mRNA CTD PMID:17484886 titanium dioxide increases expression ISO RGD:1619683 6480464 titanium dioxide results in increased expression of GPR176 mRNA CTD PMID:23557971 titanium dioxide multiple interactions ISO RGD:1619683 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA CTD PMID:29950665 titanium dioxide decreases expression ISO RGD:1619683 6480464 titanium dioxide results in decreased expression of GPR176 mRNA CTD PMID:29264374 topotecan increases expression EXP 6480464 Topotecan results in increased expression of GPR176 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GPR176 mRNA CTD PMID:25729387 triclosan decreases expression ISO RGD:737562 6480464 Triclosan results in decreased expression of GPR176 mRNA CTD PMID:30510588 valproic acid increases expression ISO RGD:737562 6480464 Valproic Acid results in increased expression of GPR176 mRNA CTD PMID:23179753 , PMID:27188386 vincaleukoblastine affects response to substance ISO RGD:737562 6480464 GPR176 protein affects the susceptibility to Vinblastine CTD PMID:16217747 vinclozolin decreases methylation EXP 6480464 vinclozolin results in decreased methylation of GPR176 gene CTD PMID:31079544 vorinostat increases expression ISO RGD:737562 6480464 vorinostat results in increased expression of GPR176 mRNA CTD PMID:27188386
Biological Process
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway acts_upstream_of_or_within ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 circadian behavior ISS UniProtKB:Q80WT4 1600115 GO_REF:0000024 UniProt GO_REF:0000024 circadian behavior ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 circadian behavior involved_in ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 circadian behavior involved_in ISS UniProtKB:Q80WT4 1600115 GO_REF:0000024 UniProt GO_REF:0000024 G protein-coupled receptor signaling pathway ISS UniProtKB:Q80WT4 1600115 GO_REF:0000024 UniProt GO_REF:0000024 G protein-coupled receptor signaling pathway ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 G protein-coupled receptor signaling pathway involved_in ISO RGD:1619683 1624291 MGI:5790765 , PMID:26882873 RGD MGI:5790765 , PMID:26882873 G protein-coupled receptor signaling pathway involved_in ISS UniProtKB:Q80WT4 1600115 GO_REF:0000024 UniProt GO_REF:0000024 G protein-coupled receptor signaling pathway involved_in IBA MGI:2685054 more ... 13792537 PMID:21873635 GO_Central G protein-coupled receptor signaling pathway IBA MGI:2685054 more ... 13792537 PMID:21873635 GO_Central
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
1358885 Bp251 Blood pressure QTL 251 3.8 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 3 10639528 127023997 Rat 1358888 Bp264 Blood pressure QTL 264 4.43 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 3 10639528 127023997 Rat 737818 Hcar12 Hepatocarcinoma resistance QTL 12 2.6 liver integrity trait (VT:0010547) volume of individual liver tumorous lesion (CMO:0001078) 3 30114912 123700444 Rat 70216 Cm14 Cardiac mass QTL 14 2.1 heart mass (VT:0007028) heart wet weight (CMO:0000069) 3 30846101 172879276 Rat 1358362 Srcrt2 Stress Responsive Cort QTL 2 2.78 blood corticosterone amount (VT:0005345) plasma corticosterone level (CMO:0001173) 3 39248391 140271184 Rat 2301970 Bw81 Body weight QTL 81 5.19 body mass (VT:0001259) body weight (CMO:0000012) 3 43295930 163640485 Rat 2301971 Cm71 Cardiac mass QTL 71 4.63 heart left ventricle mass (VT:0007031) heart left ventricle weight (CMO:0000776) 3 43295930 163640485 Rat 1581503 Cm58 Cardiac mass QTL 58 2.7 0.05 heart left ventricle mass (VT:0007031) heart left ventricle weight to body weight ratio (CMO:0000530) 3 45406058 127023997 Rat 1559282 Emca5 Estrogen-induced mammary cancer QTL 5 3.9 mammary gland integrity trait (VT:0010552) percentage of study population developing mammary tumors during a period of time (CMO:0000948) 3 45406058 177699992 Rat 2292591 Esta4 Estrogen-induced thymic atrophy QTL 4 thymus mass (VT:0004954) thymus wet weight (CMO:0000855) 3 48561928 155263151 Rat 1358186 Ept2 Estrogen-induced pituitary tumorigenesis QTL 2 8.3 pituitary gland mass (VT:0010496) pituitary gland wet weight (CMO:0000853) 3 48562146 115249962 Rat 2292613 Ept16 Estrogen-induced pituitary tumorigenesis QTL 16 8.3 pituitary gland mass (VT:0010496) pituitary gland wet weight (CMO:0000853) 3 48562146 115249962 Rat 631665 Bw8 Body weight QTL 8 5.5 body mass (VT:0001259) body weight (CMO:0000012) 3 51821836 124513579 Rat 724523 Tsu1 Thymus enlargement suppressive QTL 1 3.84 thymus mass (VT:0004954) thymus weight to body weight ratio (CMO:0000612) 3 51822008 120917851 Rat 1582218 Bw74 Body weight QTL 74 3.9 0.0021 body mass (VT:0001259) body weight (CMO:0000012) 3 54630948 119830094 Rat 1582238 Bw68 Body weight QTL 68 3.2 0.0064 body mass (VT:0001259) body weight (CMO:0000012) 3 54630948 119830094 Rat 1582239 Epfw1 Epididymal fat weight QTL 1 4.5 0.0006 epididymal fat pad mass (VT:0010421) epididymal fat pad weight to body weight ratio (CMO:0000658) 3 54630948 119830094 Rat 1581568 Rf53 Renal function QTL 53 total urine protein amount (VT:0000032) urine protein excretion rate to body weight ratio (CMO:0001099) 3 58204463 170534769 Rat 8662816 Vetf4 Vascular elastic tissue fragility QTL 4 4 renal artery integrity trait (VT:0010642) number of ruptures of the internal elastic lamina of the renal arteries (CMO:0002563) 3 61241033 165369047 Rat 1300111 Rf12 Renal function QTL 12 3.78 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 3 62922868 127023997 Rat 1582221 Kidm30 Kidney mass QTL 30 3.5 0.0008 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 3 66711607 119830094 Rat 1582210 Bw71 Body weight QTL 71 3.3 0.0012 body mass (VT:0001259) body weight (CMO:0000012) 3 66711607 119830094 Rat 12879848 Bw181 Body weght QTL 181 0.015 body mass (VT:0001259) body weight (CMO:0000012) 3 72672290 127023997 Rat 2301414 Kidm37 Kidney mass QTL 37 0.001 kidney mass (VT:0002707) both kidneys wet weight to body weight ratio (CMO:0000340) 3 72973445 127023997 Rat 1600376 Arunc5 Aerobic running capacity QTL 5 0.21 exercise endurance trait (VT:0002332) maximum distance run on treadmill (CMO:0001406) 3 78700444 123700444 Rat 1581546 Pur13 Proteinuria QTL 13 2.93 0.0335 total urine protein amount (VT:0000032) urine protein excretion rate (CMO:0000759) 3 81136227 154416635 Rat 2302273 Gluco35 Glucose level QTL 35 5.3 0.001 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 83817637 119509260 Rat 7387306 Bw124 Body weight QTL 124 3.2 0.0003 body mass (VT:0001259) body weight (CMO:0000012) 3 88910015 133910015 Rat 631649 Bp123 Blood pressure QTL 123 3.2 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 3 94788365 139788365 Rat 8694437 Bw167 Body weight QTL 167 22.46 0.001 retroperitoneal fat pad mass (VT:0010430) retroperitoneal fat pad weight to body weight ratio (CMO:0000635) 3 97009185 142009185 Rat 631841 Niddm39 Non-insulin dependent diabetes mellitus QTL 39 3.36 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 99465522 168732722 Rat 1582219 Bw63 Body weight QTL 63 3.8 0.001 body mass (VT:0001259) body weight (CMO:0000012) 3 100730984 119830094 Rat 724532 Cm17 Cardiac mass QTL 17 2 heart mass (VT:0007028) calculated heart weight (CMO:0000073) 3 101058963 146058963 Rat 2293087 Iddm27 Insulin dependent diabetes mellitus QTL 27 2.68 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 3 102152812 155263151 Rat 1354611 Despr2 Despair related QTL 2 3.03 0.0028 locomotor behavior trait (VT:0001392) amount of time spent in voluntary immobility (CMO:0001043) 3 102466149 147466149 Rat 2312659 Slep7 Serum leptin concentration QTL 7 0.001 blood leptin amount (VT:0005667) serum leptin level (CMO:0000780) 3 103141814 176418101 Rat 2312670 Bw94 Body weight QTL 94 0.01 inguinal fat pad mass (VT:0010424) inguinal fat pad weight to body weight ratio (CMO:0001253) 3 103141814 176418101 Rat 2312673 Scl63 Serum cholesterol level QTL 63 0.001 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 3 103141814 176418101 Rat 2302373 Gluco39 Glucose level QTL 39 5.01 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 3 103141944 170934860 Rat 1582216 Bw65 Body weight QTL 65 6.3 body mass (VT:0001259) body weight (CMO:0000012) 3 106900427 119830094 Rat
